A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (vol 138, pg 237, 2019): A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)

Sven J. van der Lee*, Erik van den Akker, Najada Stringa, Marc Hulsman, Niccolo Tesi, P. Alexopoulos, G. Rossi, J. van der Zee, Marcel J.T. Reinders, More Authors

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorScientificpeer-review

Fingerprint

Dive into the research topics of 'A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (vol 138, pg 237, 2019): A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)'. Together they form a unique fingerprint.

Medicine & Life Sciences